LCAHA (LCA hydroxyamide) 是一种脱泛素酶 USP2a 抑制剂,在 Ub-AMC 分析和 Di-Ub 分析中, IC50 分别为 9.7 μM 和 3.7 μM。LCAHA 通过抑制去泛素酶 USP2a 破坏细胞周期蛋白 D1 稳定性并诱导 G0/G1 期阻滞。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
LCAHA (LCA hydroxyamide) is a deubiquitinase USP2a inhibitor with IC50s of 9.7 μM and 3.7μM in Ub-AMC Assay and Di-Ub Assay, respectively. LCAHA destabilizes Cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a[1].
LCAHA inhibits HCT116wt and HCT116 p53-/- colon cancer cells viability with GI50s of 0.87±0.09 and 0.96±0.29μM, respectively, and the LD50s of 27.8±3.9 and 26.5±0.1μM, respectively[1].
[1]. Katarzyna Magiera, et al. Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G 0/G1 Arrest by Inhibiting Deubiquitinase USP2a. Cell Chem Biol. 2017 Apr 20;24(4):458-470.e18.
没有评价数据